Log in
Enquire now
‌

US Patent 10981905 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents

Patent 10981905 was granted and assigned to Xenon Pharmaceuticals on April, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Xenon Pharmaceuticals
Xenon Pharmaceuticals
Current Assignee
Xenon Pharmaceuticals
Xenon Pharmaceuticals
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10981905
Date of Patent
April 20, 2021
Patent Application Number
16556055
Date Filed
August 29, 2019
Patent Citations
‌
US Patent 10246453 Benzenesulfonamide compounds and their use as therapeutic agents
Patent Citations Received
‌
US Patent 11639351 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
0
Patent Primary Examiner
‌
Charanjit Aulakh
Patent abstract

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10981905 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.